Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
NCT ID: NCT05212779
Last Updated: 2024-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
45 participants
OBSERVATIONAL
2022-10-07
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
NCT05763511
Circulating Tumor DNA Study in Patients With Endometrial Cancer
NCT05955079
Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer
NCT05379907
Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer
NCT01187602
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
NCT04604613
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Females with Stage II-IV epithelial ovarian cancer
All patients, as participation requirements in this study, are required to have blood drawn at the completion of their adjuvant treatment. Blood sample should be collected within 6 weeks of receiving the last cycle of adjuvant chemotherapy.
Other optional time points which will be encouraged but not required:
1. After debulking surgery
2. Serial draws every 3 months while on maintenance or surveillance.
Signatera testing
26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
Altera Testing
6ml blood and tissue sample.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Signatera testing
26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
Altera Testing
6ml blood and tissue sample.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
95 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John Nakayama, MD
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Nakayama, MD
Role: PRINCIPAL_INVESTIGATOR
Allegheny Health Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AHN West Penn Hospital
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Signatera
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.